AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30055336
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss treatment delivered by peer coaches over 18 months
Trial: 30055336
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss treatment delivered by peer coaches
Trial: 24852376
Drug: Nitazoxanide 600
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide 600 mg twice daily for 5 days
Trial: 24852376
Drug: Nitazoxanide 300
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide 300 mg twice daily for 5 days
Trial: 19682359
Drug: Rapid reduction
RxNorm normalized name: MEADOWFOAM SEED OIL 4 mg in 100 g / CHRYSANTHELLUM INDICUM FLOWER 3 mg in 100 g / MENTHA ARVENSIS FLOWER OIL 2 mg in 100 g / SACCHARUM OFFICINARUM WHOLE 2 mg in 100 g / ROSMARINUS OFFICINALIS FLOWER 2 mg in 100 g / JOJOBA OIL 4 mg in 100 g / CENTELLA ASIATICA ROOT 2 mg in 100 g / AGAVE TEQUILANA LEAF 5 mg in 100 g / HAMAMELIS VIRGINIANA TOP WATER 4 mg in 100 g TOPICAL CREAM [MELAO Rapid Reduction Eye Cream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid reduction with nicotine patches and acute nicotine replacement therapy
Trial: 19682359
Drug: Standard abrupt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard abrupt cessation with nicotine patches only
Trial: 17633358
Drug: Conventional and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional and symptomatic treatment (Control)
Trial: 14999518
Drug: Antithyroid drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drug plus intranasal calcitonin (group 2)
Trial: 14999518
Drug: Antithyroid drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drug (group 1)
Trial: 14999518
Drug: Antithyroid drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid drug (group 1) and Antithyroid drug plus intranasal calcitonin (group 2)
Trial: 11600827
Drug: Triple-therapy protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-therapy protocol (zidovudine/lamivudine or stavudine/didanosine or stavudine/lamivudine with protease inhibitor)
Trial: 11600827
Drug: Treatment intensification
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment intensification protocol (ritonavir/saquinavir or ritonavir/saquinavir/stavudine)
Trial: 11600827
Drug: Discontinued study
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinued study medication
Trial: 3289770
Drug: Succinylcholine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1.5 mg.kg‐1 after pre‐treatment with d‐tubocurarine 0.05 mg.kg‐1
Trial: 3289770
Drug: Atracurium 350
RxNorm normalized name: Atracurium
DrugBank: Atracurium (DB13295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atracurium 350 micrograms.kg‐1 after a priming dose of 50 micrograms.kg‐1
Trial: 31867653
Drug: Cigarettes with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarettes with <15.8 mg/g nicotine
Trial: 31867653
Drug: Higher nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher nicotine doses (2.4, 5.2, and 15.8 mg/g of tobacco)
Trial: 26116711
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1,800 mg/day for 4 days plus 2,700 mg before the experimental session
Trial: 9049659
Drug: AM3 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AM3 treatment
Trial: 3011891
Drug: Lacto-ovo-vegetarian (L-O-V)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacto-ovo-vegetarian (L-O-V) diet
Trial: 28746788
Drug: Dexamethasone regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone regimen (day 1: intravenous dexamethasone [20 mg] and granisetron [3 mg] before TACE; days 2 and 3: intravenous dexamethasone [8 mg])
Trial: 28746788
Drug: Control regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control regimen (day 1: intravenous placebo [saline] and granisetron [3 mg]; days 2 and 3: intravenous placebo)
Trial: 16671258
Drug: Succinylcholine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (1 mg x Kg(-1)) followed by Mivacurium (100 microg x Kg(-1))
Trial: 16671258
Drug: Succinylcholine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (1 mg x Kg(-1)) preceded by Mivacurium (10 microg x Kg(-1)) and followed by Mivacurium (100 microg x Kg(-1))
Trial: 12858075
Drug: Adjunctive therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive therapies (corticosteroids, antiplatelet drugs, immunosuppressive agents)
Trial: 9183482
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solutions (ORS)
Trial: 2419292
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (CTX) followed by standard treatment (STD RX)
Trial: 2419292
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (STD RX; preoperative irradiation and radical excision or irradiation alone)
Trial: 2419292
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (STD RX)
Trial: 25421518
Drug: Treatment dropouts
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment dropouts (n=185)
Trial: 20127419
Drug: ICD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD treatment with ACE medication
Trial: 20127419
Drug: ICD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD treatment without ACE medication
Trial: 15790985
Drug: Salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone propionate combination 50/500 microg twice daily
Trial: 9763554
Drug: ATRA followed
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATRA followed by chemotherapy (CT)
Trial: 7828253
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine with saline PCEA (Group 2)
Trial: 7828253
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine without saline PCEA (Group 3)
Trial: 2969638
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day of HPR
Trial: 2969638
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day of HPR
Trial: 2969638
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day of HPR
Trial: 1385959
Drug: Niceritrol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niceritrol 1.5 g daily for 12 weeks (b.i.d.)
Trial: 1385959
Drug: Niceritrol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niceritrol 1.5 g daily for 12 weeks (t.i.d.)
Trial: 1385959
Drug: Niceritrol in
RxNorm normalized name: niceritrol
DrugBank: Niceritrol (DB13441)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niceritrol in patients with initially high Lp(a) (≥20 mg/dl)
Trial: 356507
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.05 mg/kg body weight)
Trial: 28349233
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) 10 mg orally twice daily for 8 weeks
Trial: 23642329
Drug: Aflibercept (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept (4 mg/kg every 2 weeks) combined with gemcitabine (1000 mg/m² i.v. weekly for 7 weeks out of 8, then weekly for 3 weeks out of 4)
Trial: 23642329
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg/m² i.v. weekly for 7 weeks out of 8, then weekly for 3 weeks out of 4) plus placebo
Trial: 23642329
Drug: Aflibercept (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept (4 mg/kg every 2 weeks) combined with gemcitabine
Trial: 23642329
Drug: Aflibercept (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aflibercept (4 mg/kg every 2 weeks)
Trial: 15204513
Drug: Qigong (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qigong (treatment group)
Trial: 11182866
Drug: 12-Step focused
RxNorm normalized name: STEP 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-Step focused group treatment
Trial: 8162480
Drug: Spa therapy
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spa therapy for chronic low back pain (3-week therapy programme)
Trial: 8162480
Drug: Spa therapy
RxNorm normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spa therapy for chronic low back pain (9 months follow-up)
Trial: 3227043
Drug: Naloxone 210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 210 mg
Trial: 3227043
Drug: Morphine 15-30
RxNorm normalized name: morphine 15 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 15-30 mg
Trial: 26791800
Drug: Triple antiemetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiemetic therapy with aprepitant, palonosetron, and dexamethasone
Trial: 26791800
Drug: Double antiemetic
RxNorm normalized name: ANTIEMETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double antiemetic therapy with palonosetron and dexamethasone
Trial: 23816610
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus extended-release dipyridamole (ASA + ERDP)
Trial: 20581703
Drug: Weekly undulating
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly undulating (WUD) strength training
Trial: 18084048
Drug: No r‐hLH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No r‐hLH treatment
Trial: 7868662
Drug: ICI 182,780,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 182,780, 12 mg daily for 7 days
Trial: 7868662
Drug: ICI 182,780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 182,780 treatment group
Trial: 3044182
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg diltiazem before induction of anesthesia
Trial: 3044182
Drug: 0.014 mg
RxNorm normalized name: phenol 0.014 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.014 mg diltiazem/kg per min over 20 min before cannulation
Trial: 3044182
Drug: 0.014 mg
RxNorm normalized name: phenol 0.014 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.014 mg diltiazem/kg per min during ECC
Trial: 21330912
Drug: Extended-dose nevirapine
RxNorm normalized name: nevirapine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-dose nevirapine
Trial: 21330912
Drug: Extended-dose nevirapine
RxNorm normalized name: nevirapine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-dose nevirapine (for mothers with CD4 > 350 cells/μl)
Trial: 19826272
Drug: Propranolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (1 mg/kg/d, max 1.98 mg/kg/d in six divided doses)
Trial: 16400058
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg I (as oral iodized oil)
Trial: 11417301
Drug: Anti-endothelial cell
RxNorm normalized name: AECA - Anti-endothelial cell antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-endothelial cell antibody (AECA) titer measurement in renal transplant recipients with acute rejection (n = 27)
Trial: 11417301
Drug: Anti-endothelial cell
RxNorm normalized name: AECA - Anti-endothelial cell antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-endothelial cell antibody (AECA) titer measurement post-rejection therapy
Trial: 1288238
Drug: UFT (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (400 mg per day for 6 months)
Trial: 3834100
Drug: Program model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Program model considering clinical decision making based on patient characteristics, intensity of care, and treatment modalities
Trial: 27919589
Drug: M +
RxNorm normalized name: Calcium + D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M + R (1% lidocaine 8 mL + morphine 2 mg + ropivacaine 20 mg)
Trial: 27919589
Drug: M +
RxNorm normalized name: Calcium + D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M + R + K (1% lidocaine 8 mL + morphine 2 mg + ropivacaine 20 mg + ketamine 20 mg)
Trial: 27919589
Drug: M +
RxNorm normalized name: Calcium + D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M + R + N (1% lidocaine 8 mL + morphine 2 mg + ropivacaine 20 mg + naloxone 2 μg)
Trial: 27919589
Drug: M +
RxNorm normalized name: Calcium + D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M + R + K + N (1% lidocaine 8 mL + morphine 2 mg + ropivacaine 20 mg + ketamine 20 mg + naloxone 2 μg)
Trial: 24930639
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + MTZ (400 mg TID) + AMX (500 mg TID) for 14 days
Trial: 20958856
Drug: 980 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 980 nm InGasAs diode laser (power 15 W, spot size 8 mm, time 3 seconds, fluence 90 J/cm(2)) applied weekly for 9 weeks
Trial: 17910603
Drug: sustained-release melatonin
RxNorm normalized name: melatonin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained-release melatonin
Trial: 16086149
Drug: Chronic opioid
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic opioid therapy with antidepressant
Trial: 12135028
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg p.o. every 12 h)
Trial: 12135028
Drug: Endoscopic ethanol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoscopic ethanol injection therapy
Trial: 10396712
Drug: Thiamylal 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamylal 4 mg/kg
Trial: 10468248
Drug: A4 (28,572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A4 (28,572 KIU/kg of aprotinin before surgery, followed by continuous infusion of 7,143 KIU/kg/h until the end of surgery)
Trial: 10468248
Drug: A2 (14,286
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A2 (14,286 KIU/kg of aprotinin before surgery, followed by continuous infusion of 7,143 KIU/kg/h until the end of surgery)
Trial: 1859488
Drug: Oral azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azathioprine plus cyclophosphamide
Trial: 6303373
Drug: Metoprolol 200
RxNorm normalized name: metoprolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 200 mg in a slow‐release tablet once daily for 4 days and 10 mg i.v. shortly before induction of anaesthesia
Trial: 6303373
Drug: Fentanyl 1.0‐1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 1.0‐1.5 mg during anaesthesia
Trial: 6303373
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets and physiological saline i.v.
Trial: 31468618
Drug: Half-dose bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Half-dose bevacizumab therapy (7.5 mg/kg every 3-4 weeks)
Trial: 29496069
Drug: Cetuximab or
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab or Bevacizumab in combination with fluorouracil, folinic acid, and irinotecan (first-line therapy)
Trial: 12431965
Drug: Marimastat 10
RxNorm normalized name: Marimastat
DrugBank: Marimastat (DB00786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marimastat 10 mg orally bid for up to 2 years
Trial: 8950069
Drug: Guided antiarrhythmic
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided antiarrhythmic therapy (class I, II, and III antiarrhythmic drugs)
Trial: 1758710
Drug: Continuous Infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Infusion (CI)
Trial: 6759059
Drug: timolol/hydrochlorothiazide/amiloride preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: timolol/hydrochlorothiazide/amiloride preparation
Trial: 26031762
Drug: Nebulized fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nebulized fentanyl (250 μg)
Trial: 24214779
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg morphine sulfate
Trial: 24214779
Drug: 0.10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.10 mg/kg morphine sulfate
Trial: 21745374
Drug: Plasma exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma exchange (PE) one volume daily for 5 days
Trial: 19966527
Drug: Lornoxicam (LOR)
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (LOR) 8 mg
Trial: 19966527
Drug: Lornoxicam (LOR)
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (LOR) 16 mg
Trial: 17445841
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (early surgery)
Trial: 9824265
Drug: Terlipressin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (2 mg/day for 2 days)
Trial: 6446778
Drug: Intravenous spectinomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous spectinomycin hydrochloride (8 g per day)
Trial: 6446778
Drug: Aqueous penicillin
RxNorm normalized name: penicillin G procaine Injectable Suspension [Pen-Aqueous]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous penicillin G (2.0 x 10(7) units per day, iv) plus kanamycin (1 g per day, im)
Trial: 23379537
Drug: OC000459 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC000459 (100 mg, twice daily)
Trial: 21110526
Drug: Adalimumab 80
RxNorm normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 80 mg at baseline followed by 40 mg every other week from week 1 to week 15
Trial: 19466961
Drug: High-dose UVB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose UVB therapy (40% incremental doses, three times weekly)
Trial: 19466961
Drug: Low-dose UVB
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose UVB therapy (20% incremental doses, three times weekly)
Trial: 11495180
Drug: Fluoxetine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (30 or 60 mg) with behavioral counseling
Trial: 9721156
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg igmesine
Trial: 9721156
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg igmesine
Trial: 8036824
Drug: Intradermal purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal purified chick embryo cell rabies vaccine (PCEC) alone (0.1 ml at each of two sites on days 0, 3, and 7, and at one site on days 28 and 90) (n = 81)
Trial: 8036824
Drug: Intradermal PCEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal PCEC with one dose of human rabies immunoglobulin (HRIG) intramuscularly at 20 IU kg‐1 on day 0 (n = 52)
Trial: 27959715
Drug: Inclisiran (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclisiran (300 mg or more, single dose)
Trial: 27959715
Drug: Inclisiran (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclisiran (100 mg or more, single dose)
Trial: 27959715
Drug: Inclisiran (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclisiran (multiple doses)
Trial: 26189484
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate 0.05% ointment (corticosteroid group)
Trial: 24204065
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (weekly for up to 14 weeks)
Trial: 19414946
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg/day for 6 months
Trial: 19414946
Drug: Vitamin B-12
RxNorm normalized name: Vitamin B-12
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B-12 500 mcg/day